In addition to their role in inflammation-induced cancers, it was demonstrated that 29% of activated B-cell-like subtype of diffuse large B-cell lymphomas harboured an amino acid substitution, L265P, in the MYD88 TIR domain, and that some rare cases had other mutations19. Here, MYD88 is linked to cancer.